Outcomes in mepolizumab patients according to adherence
| All patients | ICS adherence | p-value | |||
| Good | Intermediate | Poor | |||
| Subjects | 91 | 62 | 13 | 16 | |
| ACQ-6 change | −0.63±1.26 | −0.76±1.18 | −0.63±1.1 | −0.15±1.6 | 0.24 |
| FEV1 % change | −2.3±14.4 | 0.7±11.2 | −6.8±19.1 | −4.9±18.8 | 0.28 |
| Change in OCS dose mg·day−1 | −8.4±5.4 | −8.9±5.5 | −9.0±5.5 | −5.8±4.1 | 0.11 |
| Median OCS reduction % baseline dose | 100 (60–100) | 100 (74–100) | 93.3 (54–100) | 60 (27–100) | 0.031 |
| >50% reduction in OCS dose | 73 (80) | 54 (87) | 10 (77) | 9 (57) | 0.021 |
| Stopped OCS | 47 (52) | 37 (60) | 5 (39) | 5 (31) | 0.075 |
| Treatment failure# | 13 (14.3) | 5 (8.1) | 2 (15.4) | 6 (37.5) | 0.011 |
| AER | 1.4±1.8 | 1.1±1.4 | 1.8±1.6 | 2.1±2.7 | 0.06 |
| Change in AER | −1.4±3.1 | −2.1±3.1 | −0.1±2.1 | 0.3±2.5 | 0.004 |
Data are presented as n, mean±sd, median (interquartile range) or n (%), unless otherwise stated. ICS: inhaled corticosteroid; ACQ: Asthma Control Questionnaire; FEV1: forced expiratory volume in 1 s; OCS: oral corticosteroid; AER: annual exacerbation rate. #: inability to reduce either daily OCS dose or AER by ≥50% after 12 months of mepolizumab therapy.